{"Clinical Trial ID": "NCT01610284", "Intervention": ["INTERVENTION 1:", "BKM120 100mg + Fulvestant", "BKM120 100 mg daily and fulvestrant administered until progression or as described in the protocol.", "INTERVENTION 2:", "Placebo + Fulvestrant", "BKM120 corresponding to placebo daily and fulvestrant administered until progression or as described in the protocol."], "Eligibility": ["Key Inclusion Criteria:", "Locally advanced or metastatic breast cancer", "HER2-negative and positive hormonal receptor status (common breast cancer classification tests)", "Menopausal women", "A tumour sample should be sent to a Novartis laboratory designated to identify biomarkers (PI3K activation status).", "Progression or recurrence of breast cancer during or after treatment of the aromatase inhibitor", "A measurable disease or non-measurable bone damage in the absence of a measurable disease according to RECIST 1.1", "A suitable bone marrow and organ function defined by laboratory values", "Key Exclusion Criteria:", "Previous treatment with PI3K inhibitors, AKT inhibitors, mTOR inhibitor or fulvestrant", "More than one previous chemotherapy line for metastatic diseases", "- Symptomatic brain metastases", "\u2022 Chronic increase or treatment (> 5 days) with corticosteroids or other immunosuppressant", "Active heart disease (cardiac) as defined in the protocol", "Some scores on an anxiety and depression mood questionnaire"], "Results": ["Performance measures:", "Based on the evaluation of local researchers - Set of Comprehensive Analyses (FAS) in the Total Population, Main Study Cohort and Unknown PI3K Study Cohort", "In addition to the relative increase of 20%, the sum should show an absolute increase of at least 5 mm.", "Time limit: Date of randomization until the date of the first documented tumour progression or death of any cause, whichever occurs first, reported between the day of the first randomised patient up to about 4 years", "Results 1:", "Title of arm/group: BKM120 100mg + Fulvestrant", "Description of the arm/group: BKM120 100 mg daily and fulvestrant administered until progression or as described in the protocol.", "Total number of participants analysed: 576", "Median (95% confidence interval)", "Unit of measure: FAS-Total population month: 576 participants", "6.9 (6.8 to 7.8)", "FAS - main cohort: 427 participants", "6.8 (5.0 to 7.0)", "The FAS-PI3K course is activated: 188 participants", "6.8 (4.9 to 7.1)", "FAS-PI3K Non-activated route: 239 participants", "6.9 (4.6 to 7.2)", "FAS-PI3K Unknown route: 149 participants", "8.7 (7.0 to 12.4)", "Results 2:", "Title of the arm/group: Placebo + Fulvestant", "Description of the arm/group: BKM120 placebo daily corresponding and fulvestrant administered until progression or as described in the protocol.", "Total number of participants analysed: 571", "Median (95% confidence interval)", "Unit of measure: FAS-Total population month: 571 participants", "5.0 (4.0 to 5.2)", "FAS - main cohort: 424 participants", "4.5 (3.3 to 5.0)", "The FAS-PI3K course is activated: 184 participants", "4.0 (3.1 to 5.2)", "FAS-PI3K Non-activated route: 240 participants", "4.6 (3.3 to 5.1)", "FAS-PI3K Unknown route: 147 participants", "- 6.8 (5.0 to 8.4)"], "Adverse Events": ["Undesirable Events 1:", "Total: 146/573 (25.48%)", "Anemia 4/573 (0.70 %)", "Disseminate intravascular coagulation 0/573 (0.00 %)", "Neutropenia 1/573 (0.17%)", "Thrombocytopenia 0/573 (0.00 %)", "Acute coronary syndrome 1/573 (0.17%)", "Angina pectoris 1/573 (0.17%)", "Atrial fibrillation 2/573 (0.35%)", "Atrial stem 0/573 (0.00 %)", "Cardiac arrest 1/573 (0.17%)", "Heart failure 0/573 (0.00 %)", "Adverse Events 2:", "Total: 101/570 (17.72 per cent)", "Anemia 3/570 (0.53%)", "Disseminate intravascular coagulation 1/570 (0.18%)", "Neutropenia 1/570 (0.18%)", "Thrombocytopenia 1/570 (0.18%)", "Acute coronary syndrome 0/570 (0.00 %)", "Angina pectoris 1/570 (0.18%)", "Atrial fibrillation 0/570 (0.00 %)", "1/570 (0.18%)", "Cardiac arrest 0/570 (0.00 %)", "Heart failure 1/570 (0.18%)"]}